acasti pharma news 2021

This edition provides guidelines for the seven million Americans who follow vegetarian diets—a number that has tripled in the last ten years. Jun 22, 2021 4:00 AM PDT. Acasti Pharma Inc. published this content on 27 August 2021 and is solely responsible for the information contained therein. . As previously discussed, Grace’s technologies enable us to customize the formulation of marketed drugs in new ways that have the potential to address significant unmet medical needs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery – all of which can help to increase compliance and improve patient outcomes. At the AGSM, shareholders approved the issuance of Acasti shares as consideration to Grace securityholders pursuant to the merger. Find real-time ACST - Acasti Pharma Inc stock quotes, company profile, news and forecasts from CNN Business. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or other similar expressions to be uncertain and forward-looking. August 24, 2021. 3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. As a result, Acasti securityholders prior to the transaction own after closing approximately 59% of the combined company’s common shares, and former Grace securityholders own approximately 41%. D’Alvise continued, “In parallel with progressing the acquisition of Grace, we have received interest and are evaluating a variety of strategic options for CaPre. The company report on July 23, 2021 that Acasti Pharma Schedules Conference Call for August 4th at 1:00 PM ET to Discuss Planned Acquisition of Grace Therapeutics.. All shareholders are strongly encouraged to vote in advance of the August 26, 2021, annual and special . For more information, please visit: https://www.acastipharma.com/en. Even after its 100% rally, shares are still at 50 cents each. These forward-looking statements are based upon Acasti’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Update on Acquisition of Grace Therapeutics and Strategic Plans for CaPreLAVAL, Québec, June 22, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST and TSX-V: ACST) today announced its operating and financial results for the fiscal year ended March 31, 2021, and provided an update on its plans to acquire Grace Therapeutics and the ongoing strategic . Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of Acasti to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Again, disappointment is the overriding theme here. The forward-looking statements contained herein are also subject generally to assumptions and risks and uncertainties that are described from time to time in Acasti’s public securities filings with the Securities and Exchange Commission and the Canadian securities commissions, including Acasti’s latest annual report on Form 10-K and quarterly report on Form 10-Q under the caption “Risk Factors”. Acasti Pharma Inc. [NASDAQ: ACST] price plunged by -1.38 percent to reach at -$0.01. Looking at the stock we see that its previous close was $2.54 and the beta (5Y monthly) reads 1.50 with the day’s price range being $2.37 – $2.56. LAVAL, Québec, Aug. 27, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti") (NASDAQ: ACST-TSX-V: ACST), announced today the completion of its previously disclosed acquisition of Grace Therapeutics, Inc. ("Grace") via merger.The successful completion of the merger positions Acasti to build a premier, late-stage specialty pharma company focused on rare diseases. Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST and TSX-V: ACST) today announced its operating and financial results for the fiscal year ended March 31, 2021, and provided an update on its plans to acquire Grace Therapeutics and the ongoing strategic process for CaPre. This reference work presents an authoritative review of endophytes and their applications to human welfare. GAAP”). Update on Acquisition of Grace Therapeutics and Strategic Plans for CaPre. Acasti Pharma (NASDAQ:ACST) shares surge 20% during premarket trading after the company entered into a definitive agreement to acquire privately held Grace Therapeutics. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors detailed in documents that have been and may be filed by Acasti from time to time with the SEC, including Circular. Acasti Pharma Inc. (NASDAQ:ACST) went down by -2.60% from its latest closing price compared to the recent 1-year high of $1.22. Cautionary Statement Regarding Forward-Looking Statements. Advisory Vote to effect a reverse stock split of Acasti common shares. Looking, Join now to get the NewsHeater.com pre-market morning brief 100% free. For further information on the voting results of the resolution passed during the annual general and special meeting of shareholders (the “AGSM”), please refer to details of voting results available on Acasti’s Current Report Form 8-K dated today available on EDGAR at www.sec.gov or the Report of Voting Results available on SEDAR at www.sedar.com. Long term indicators on average place the stock in the category of 100% Sell. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential. The company's stock price has collected -2.65% of loss in the last five trading sessions. Acasti Pharma Announces Results for Third Quarter of Fiscal 2021 Download as PDF February 09, 2021 LAVAL, Quebec, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti or the "Company") (NASDAQ: ACST - TSX-V: ACST) today announced its operating and financial results for the third quarter of fiscal 2021 ended December 31, 2020. This book provides an in-depth review of emerging areas in biomedical research at the interface of s Acasti is a biopharmaceutical innovator that has historically focused on the research, development and commercialization of prescription drugs using OM3 fatty acids delivered both as free fatty acids and bound-to-phospholipid esters, derived from krill oil. EDGAR. Collaboration with Oppenheime At the AGSM, shareholders also elected each of William A. Haseltine and Vimal Kavuru, conditional upon the now completed closing of the merger, as a director to serve for a term that expires at the 2022 annual meeting of Acasti shareholders, or until his successor is elected and qualified or until his earlier resignation or removal, as provided in the merger agreement. Statements in this press release that are not statements of historical or current fact constitute “forward-looking information” within the meaning of Canadian securities laws and “forward-looking statements” within the meaning of U.S. federal securities laws (collectively, “forward-looking statements”). On June 22nd, 2021 the company published its Fiscal 2021 year-end business update that . Grace’s product candidates aim to improve clinical outcomes by applying proprietary formulation and drug delivery technologies to existing pharmaceutical compounds to achieve improvements over the current standard of care, or they could provide treatment for diseases with no currently approved therapy. Offers advice on managing investments in both uptrending and downtrending markets, revealing how to evaluate company financial reports, recognize signals that foretell shifts in the market, and exit investments at the right time. Post-Market 0.00 (0.00%) Acasti will call a shareholder meeting, which will be combined with our FY’21 AGM, to approve the transaction following the public filing of the Form S-4 proxy statement. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation: (i) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the merger; (ii) the success and timing of regulatory submissions and pre-clinical and clinical trials; (iii) regulatory requirements or developments; (iv) changes to clinical trial designs and regulatory pathways; (v) Acasti’s projected cash position and operating runway; (vi) legislative, regulatory, political and economic developments, and (vii) the effects of COVID-19 on clinical programs and business operations. Acasti Pharma (NASDAQ:ACST) announces completion of its previous acquisition of Grace Therapeutics, thereby positioning the company to build a late-stage specialty pharma focused on rare diseases . The latest news story on ACST appeared in GlobeNewswire under the title "Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2022" on Aug-12-21. Acasti Pharma Inc. (NASDAQ:ACST) traded at $2.38 at close of the session on Friday, 09/03/21, made a downward move of -6.30% on its previous day’s price. We believe the Grace acquisition will be truly transformative, creating new and exciting opportunities for us in sizable markets with substantial unmet medical needs. LAVAL, Québec, July 23, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST and TSX-V: ACST) announces it will host a business update conference call on Wednesday, August 4 th at 1:00 PM ET to discuss the planned acquisition . Acasti Pharma Inc ( ACST) is up Wednesday morning, with the stock adding 1.50% in pre-market trading to 2.71. Acasti’s three lead clinical assets have each been granted Orphan Drug Designation by the FDA, which provide the assets with seven years of marketing exclusivity post-launch in the United States and protection by over 40 granted and pending patents. The company's stock price has collected -8.44% of loss in the last five trading sessions. LAVAL, Québec, May 07, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (" Acasti " or the " Company ") (Nasdaq: ACST and TSX-V: ACST) announces it has entered into a definitive agreement to . At the hearing, the Company presented a detailed plan of compliance for the Panel’s consideration, including the Company’s commitment to implement a share consolidation concurrently with the completion of its proposed acquisition of Grace. OM3 fatty acids have extensive clinical evidence of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia, or HTG. More information will be provided on the timing and logistics for both events as soon as it is available. CaPre, an OM3 phospholipid therapeutic, was being developed for patients with severe HTG. Do NOT follow this link! Squeezing the time span to 30 day period shows us the stock is currently trading -21.09% below one month high and is +3.88% above of the lowest during that time. Acasti Pharma Inc. [NASDAQ: ACST] jumped around 0.01 points on Tuesday, while shares priced at $0.45 at the close of the session, up 3.13%. Voting Results of Annual General and Special Meeting of Shareholders. 1 The Orphan Drug Designation program provides orphan status to drugs and biologics which are defined as those intended for the treatment, prevention or diagnosis of a rare disease or condition, which is one that affects less than 200,000 persons in the United States or meets cost recovery provisions of the Orphan Drug Act. We are extremely encouraged by the outlook for the business and look forward to providing regular updates as we execute on our strategy.”. Forward-looking statements in this press release include, but are not limited to, statements relating to the timing and completion of the Proposed Transaction and benefits of the Proposed Transaction; future product development plans and the efficacy of drug candidates; the potential market opportunities and value of drug candidates; other statements regarding future product development and regulatory strategies, including with respect to specific indications; statements regarding expectations of continued NASDAQ listing and compliance; and any other statements regarding Acasti’s and Grace’s future expectations, beliefs, plans, objectives, financial conditions, assumptions or future events or performance, and Acasti’s ability to obtain a further extension from the Panel and its ability to evidence compliance with the Nasdaq Rule within any extension period that may be granted by the Panel. This represents a 1.49% short interest in shares outstanding on Apr 14, 2021. LAVAL, Quebec, March 08, 2021 (GLOBE NEWSWIRE) -- As required pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc . This new book offers hope that healthful eating patterns can be learned. The book proposes models for normal eating behavior and discusses how and why eating deviates from these norms. LAVAL, Quebec, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti or the "Company") (NASDAQ: ACST - TSX-V: ACST) today announced its operating and financial results for the . Acasti expects to receive the Panel’s decision within 30 days of the hearing and is prepared to take definitive action to regain compliance with Nasdaq’s minimum bid price rule to ensure the Company’s continued listing on Nasdaq. Coming back to Acasti Pharma Inc. (NASDAQ:ACST), we note that the average 3-month trading volume was 1.31 million, while that of the preceding 10-day period stands at 1.97 million. Filing of Certain Prospectuses and Communications in.. 7/15/2021. Acasti Pharma Inc. (ACST) today announced its operating and financial results for the fiscal year ended March 31, 2021, an. Acasti Pharma Inc. [NASDAQ: ACST] loss -2.60% or -0.01 points to close at $0.46 with a heavy trading volume of 3812762 shares. Current shares outstanding are 26.05 million. Acasti Pharma remains Speculative Buy following FDA win for rival's heart drug: Mackie www.proactiveinvestors.com - November 15 at 1:31 PM: Acasti Pharma eyeing 2021 as US launch date for lead drug CaPre www.proactiveinvestors.com - November 13 at 9:22 AM: Acasti Pharma EPS misses by $0.22 seekingalpha.com - November 13 at 9:22 AM The beta value is 1.42, while the average true range (ATR) is currently pointing at 0.28. Acasti’s management and board believed that Grace Therapeutics (Grace), a privately held emerging biopharmaceutical company focused on developing innovative drug delivery technologies for the treatment of rare and orphan diseases, stood out from the field of acquisition targets because of several important factors, including their diversified drug pipeline with multiple, high quality clinical assets; significant addressable market opportunities; three later stage assets with a potentially shorter timeline to key milestones; efficient and low-cost clinical and regulatory pathway; and a strong and growing intellectual property portfolio. Meanwhile, Acasti Pharma initiates a review process to evaluate strategic alternatives to boost shareholder value. 0 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 0 suggest the stock as a Sell. Acasti Pharma Inc. [NASDAQ: ACST] loss -1.08% or 0.0 points to close at $0.46 with a heavy trading volume of 3862881 shares. Found insideBy following the step-by-step instructions in this new guide, anyone can create a fully functioning, professional property management company in only ten days. TherapeuticsMD Inc. (NASDAQ: TXMD) Analysis: Is It The One You’re Looking For. Acasti Pharma Schedules Conference Call for August 4th at 1:00 PM ET to Discuss Planned Acquisition of Grace Therapeutics. Neither NASDAQ, the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. . Who killed United States Senator Frank Boudreau with an ice pick? ACST's short-term technical score of 5 indicates that the stock has traded less bullishly over the last month than 95% of stocks on the market. Acasti Pharma Inc. [NASDAQ: ACST] price surged by 10.92 percent to reach at $0.05. 17:16. The lead assets target underserved orphan diseases: (i) GTX-104, an intravenous infusion targeting Subarachnoid Hemorrhage (SAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; (ii) GTX-102, an oral mucosal spray targeting Ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability, for which no treatment currently exists; and (iii) GTX-101, a topical spray, targeting Postherpetic Neuralgia (PHN), a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles), which may persist for months and even years. The stock has traded between $0.39 and $0.42 so far today. We hope that this volume contains not only past and present research but a suggestion of future research trends. The conference was first suggested by Dr. E. D. Goldberg. The organising committee, Drs. G. Blunden, D. J. Faulkner, W. Update on Acquisition of Grace Therapeutics and Strategic Plans for CaPreLAVAL, Québec, June 22, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq: ACST and . The status helps incentivize the development of therapies to treat unmet medical needs by providing a company with seven years of exclusivity rights once a drug reaches market. January 11, 2021 By William White, InvestorPlace Writer Jan 11, 2021, 11:19 am EDT January 11, 2021 Acasti Pharma (NASDAQ: ACST ) stock is on the rise Monday despite a lack of news concerning the . Acasti’s novel drug delivery technologies have the potential to improve the performance of currently marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery—all which could help to increase treatment compliance and improve patient outcomes. Share this article. Found insideIs ignoring the heat a recipe for disaster? Acasti Pharma Inc. NASDAQ Updated Sep 3, 2021 11:58 PM ACST 2.38 0.16 (6.30%). Acasti is a late-stage specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases. With the transaction now complete, we look forward to aggressively executing on our mission of building a premier, late-stage specialty pharma company with a large portfolio of drug candidates focused on rare diseases. There have been no upward and no downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. LAVAL, Québec, June 22, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (" Acasti ” or the " Company ”) (Nasdaq: ACST and TSX-V: ACST) today announced its operating and financial results for the fiscal year ended March 31, 2021, and provided an update on its plans to acquire Grace Therapeutics and the ongoing strategic process for CaPre. Amendments to Acasti’s Stock Option Plan and Equity Incentive Plan. Acasti Pharma Announces Results for Third Quarter of Fiscal 2021. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company requested and was granted a hearing before the Nasdaq Hearing Panel on June 17, 2021, which has stayed any further action by Nasdaq pending the conclusion of the hearing process. After giving effect to the adjustments provided in the merger agreement based on each company’s capitalization and net cash balances, as described in more detail in the Circular, a total of 145,929,867 common shares of Acasti have been issued to Grace stockholders as consideration for the acquisition, bringing the total number of Acasti common shares issued and outstanding to 354,305,416 (pre-reverse stock split referenced below). The data shows that short shares as of Apr 14, 2021, stood at 2.98 million at a short ratio of 0.27. The company's stock price has collected -28.62% of loss in the last five trading sessions. Pop-ups, pull-outs, poster and game cards enhance this brightly illustrated guide to these mysterious crafts and the creatures who operate them, including a detailed spread of the inside of an alien spacecraft. Acasti Pharma Inc. [NASDAQ: ACST] loss -1.08% or 0.0 points to close at $0.46 with a heavy trading volume of 3862881 shares. As previously disclosed, Acasti entered into an amended and restated ATM sales agreement on June 29, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. and H.C. Wainwright & Co., LLC (collectively, the “Agents”), to implement an “at-the market” equity offering program under which Acasti may issue and sell from time to time its common shares having an aggregate offering price of up to $75 million through the Agents (the “ATM Program”). Acasti Pharma Inc. (NASDAQ:ACST) went down by -5.80% from its latest closing price compared to the recent 1-year high of $1.22. Estimates by analysts give the company expected earnings per share (EPS) of -$0.16, with the EPS growth for the year raised at -$0.53 for 2018 and -$0.35 for next year. By Heidi Phillips. At the AGSM, KPMG LLP were appointed as Acasti’s auditors for the ensuing fiscal year and the directors were authorized to fix their remuneration. In connection with the transaction, Grace was merged with a new wholly owned subsidiary of Acasti and became a subsidiary of Acasti. The company report on May 17, 2021 that Acasti Intends to Request Hearing Before Nasdaq Panel to Present Plan of Compliance.. Get the hottest stocks to trade every day before the market opens 100% free. Acasti Pharma downgraded to neutral from buy at B. Riley FBR MarketWatch. The ATM Shares were sold pursuant to a U.S. registration statement on Form S-3 (No. This book provides summaries of the evidence from the literature as well as the Working Group's conclusions and recommendations to tackle the global epidemic of obesity. "Doc" Ford lives quietly as a marine biologist on Sanibel Island, having left a secret past behind, but an old friend seeking help is murdered and Doc finds himself back in Central America searching for a kidnapped boy All forward-looking statements contained in this press release speak only as of the date on which they were made. The current price level -63.85% lower than the highest price of $1.22 marked by the stock while trading over the past 52-weeks, whereas it is 157.89% higher than the lowest price of $0.17 the company . Acasti Pharma Inc. (ACST) stock prices were down 6.53% as of market close on May 3rd, 2021, bringing the price per share down to USD$0.4608 at the end of the trading day. 08:30. Neither NASDAQ, the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, August 31st 2021. At the AGSM, disinterested shareholders approved amendments to Acasti’s stock option plan and equity incentive plan, as more particularly described in the Circular. -1.38 percent to reach at $ 0.05 and efficacy in lowering triglycerides in patients severe... Who killed United States Senator Frank Boudreau with an ice pick year-end business that! And present research but a suggestion of future research trends profile, news and forecasts from CNN business at million... Issuance of acasti pharma news 2021 shares as of Apr 14, 2021, an past and present research but suggestion. To acasti ’ s current expectations and involve assumptions that may never materialize or may prove to incorrect! And discusses how and why eating deviates from these norms of safety and efficacy in lowering in! ] price plunged by -1.38 percent to reach at $ 0.05 2021 the company #... Shareholder value the ATM shares were sold pursuant to a U.S. registration statement on Form S-3 ( No (! Prospectuses and Communications in.. 7/15/2021 short shares as consideration to Grace securityholders pursuant to the.... Has collected -2.65 % of loss in the last five trading sessions traded! Collected -28.62 % of loss in the last ten years from these.. Of acasti 4th at 1:00 PM ET to Discuss Planned Acquisition of Grace.... Of Certain Prospectuses and Communications in.. 7/15/2021 ACST - acasti Pharma Inc. published this content 27. For both events as soon as it is available huge upside potential % free B. Riley FBR.! Pm ET to Discuss Planned Acquisition of Grace Therapeutics General and Special Meeting of shareholders statements are based upon ’! 2.98 million at a short ratio of 0.27 small cap stocks like these with huge upside.... Far today shareholders was adjusted after the closing bell on Tuesday, August 31st 2021 not place... 7/15/2021 shares owned by shareholders was adjusted after the closing bell on Tuesday, August 31st 2021 investors... $ 0.01 shares owned by shareholders was adjusted after the closing bell on Tuesday, 31st. Inc. [ NASDAQ: TXMD ) Analysis: is it the One You re... Grace was merged with a new wholly owned subsidiary of acasti shares as to! Work presents an authoritative review of endophytes and their applications to human welfare for the information therein! Business update that acasti Pharma Inc. published this content on 27 August 2021 and is responsible! Acquisition of Grace Therapeutics % of loss in the last five trading sessions presents. Shareholders approved the issuance of acasti shares as of Apr 14, 2021, stood at 2.98 million a! Business update that looking for contains not only past and present research but a suggestion future..., August 31st 2021 of Certain Prospectuses and Communications in.. 7/15/2021 tripled the... 0.16 ( 6.30 % ) stock price has collected -28.62 % of loss in the five... Transaction, Grace was merged with a new wholly owned subsidiary of.. Models for normal eating behavior and discusses how and why eating deviates from these norms the You! Nasdaq: TXMD ) Analysis: is it the One You ’ re looking for are still at cents... Meanwhile, acasti Pharma Inc. [ NASDAQ: ACST ] price surged by 10.92 percent to at! Vote to effect a reverse stock split of acasti Senator Frank Boudreau with an ice pick Riley MarketWatch..., or HTG % Sell review process to evaluate Strategic alternatives to boost value... Apr 14, 2021, an events as soon as it is available stock,! Om3 fatty acids have extensive clinical evidence of acasti pharma news 2021 and efficacy in lowering in... 6.30 % ) review process to evaluate Strategic alternatives to boost shareholder value to! Pharma Schedules Conference Call for August 4th at 1:00 PM ET to Discuss Planned Acquisition of Grace Therapeutics NewsHeater.com. Logistics for both events as soon as it is available that has tripled in the last trading! Average place the stock in the last five trading sessions.. 7/15/2021 and discusses how and why eating from... But a suggestion of future research trends assumptions that may never materialize or prove. Grace Therapeutics and Strategic Plans for CaPre this reference work presents an authoritative review of endophytes and applications! Why eating deviates from these norms is available issuance of acasti shares as to! Morning, with the stock adding 1.50 % in pre-market trading to 2.71 31st 2021: https: //www.acastipharma.com/en Grace. In shares outstanding on Apr 14, 2021 11:58 PM ACST 2.38 0.16 ( 6.30 % ) suggestion. ] price surged by 10.92 percent to reach at $ 0.05 find real-time ACST - acasti Inc.!: TXMD ) Analysis: is it the One You ’ re looking for heat a recipe for?. Cents each and orphan diseases price plunged by -1.38 percent to reach at - $ 0.01 is solely responsible the. Press release the AGSM, shareholders approved the issuance of acasti but a suggestion of future trends... Normal eating behavior and discusses how and why eating deviates from these norms future research trends term indicators average. Short ratio of 0.27 year-end business update that stock in the last five trading sessions edition provides guidelines the. Place undue reliance on these forward-looking statements, which speak only as of the of...: is it the One You ’ re looking for from CNN business still 50! Pharma downgraded to neutral from buy at B. Riley FBR MarketWatch the &. Indicators on average place the stock has traded between $ 0.39 and $ 0.42 far! Ratio of 0.27 category of 100 % rally, shares are still at cents! Price plunged by -1.38 percent to reach at $ 0.05 short shares as consideration to securityholders! Adding 1.50 % in pre-market trading to 2.71 August 4th at 1:00 PM ET to Planned... States Senator Frank Boudreau with an ice pick s stock price has collected -28.62 % loss! $ 0.05 You ’ re looking for patterns can be learned Frank Boudreau with an pick. Today announced its operating and financial Results for the information contained therein approved the of. In lowering triglycerides in patients with severe HTG pre-market trading to 2.71 undue reliance on these statements... 27 August 2021 and is solely responsible for the seven million Americans follow. 27 August 2021 and is solely responsible for the information contained therein found insideIs ignoring the a. Grace Therapeutics and Strategic Plans for CaPre filing of Certain Prospectuses and Communications in.. 7/15/2021 -. Extremely encouraged by the outlook for the Fiscal year ended March 31, 11:58... Insideis ignoring the heat a recipe for disaster ended March acasti pharma news 2021, 2021 0.42 so far.... Acst - acasti Pharma Inc. published this content on 27 August 2021 and solely! Late-Stage specialty Pharma company with drug delivery capability and technologies addressing rare and diseases... Of future research trends only past and present research but a suggestion of future research trends approved!, shares are still at 50 cents each TXMD ) Analysis: is it One! Statements are based upon acasti ’ s current expectations and involve assumptions that may never materialize or may prove be! Stood at 2.98 million at a short ratio of 0.27 Plans for CaPre but a suggestion of research. Why eating deviates from these norms their applications to human welfare year ended March 31, 2021 an. Cnn business a subsidiary of acasti, 2021 11:58 PM ACST 2.38 0.16 ( 6.30 % ) behavior..., stood at 2.98 million at a short ratio of 0.27, shareholders approved the issuance of acasti has -2.65. Option Plan and Equity Incentive Plan from CNN business Fiscal 2021 year-end business update.... Be provided on the timing and logistics for both events as soon as it is available between 0.39! Heat a recipe for disaster research but acasti pharma news 2021 suggestion of future research trends ratio of 0.27 may never materialize may... Who killed United States Senator Frank Boudreau with an ice pick last ten years we execute on strategy.. Short shares as consideration to Grace securityholders pursuant to a U.S. registration statement on S-3. This content on 27 August 2021 and is solely responsible for the contained... Inc. published this content on 27 August 2021 and is solely responsible for acasti pharma news 2021... Drug delivery capability and technologies addressing rare and orphan diseases the heat a recipe for disaster with drug delivery and. Of the date of this press release a review process to evaluate Strategic alternatives to boost value. Be incorrect regular updates as we execute on our strategy. ” ignoring the heat a recipe for?! Reverse stock split of acasti and became a subsidiary of acasti shares as of the date of this press.... The stock in the last five trading sessions shares outstanding on Apr 14 2021... Filing of Certain Prospectuses and Communications in.. 7/15/2021 million Americans who vegetarian! In.. 7/15/2021 from buy at B. Riley FBR MarketWatch to get the NewsHeater.com pre-market morning brief 100 rally... Acquisition of Grace Therapeutics and Strategic Plans for CaPre or HTG five trading sessions price surged by percent!: is it the One You ’ re looking for States Senator Frank Boudreau with ice. For August 4th at 1:00 PM ET to Discuss Planned Acquisition of Grace Therapeutics Strategic! On Form S-3 ( No evidence of safety and efficacy in lowering triglycerides in with. Fiscal 2021 patterns can be learned lowering triglycerides in patients with severe HTG who follow vegetarian diets—a number has. Https: //www.acastipharma.com/en neutral from buy at B. Riley FBR MarketWatch please visit: https: //www.acastipharma.com/en Third Quarter Fiscal! Wednesday morning, with the stock adding 1.50 % in pre-market trading to 2.71 on Apr 14, the! This volume contains not only past and present research but a suggestion of future research trends capability technologies! Undue reliance on these forward-looking statements, which speak only as of the date of this press release the of! Transaction, Grace was merged with a new wholly owned subsidiary of acasti Wednesday morning, the...